AVITA Medical (RCEL) 10-Q 10 Nov 20 2021 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Sep. 30, 2020	Nov. 06, 2020
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2020
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	Avita Therapeutics, Inc.
Entity Central Index Key	0001762303
Current Fiscal Year End Date	--06-30
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Security Exchange Name	NASDAQ
Trading Symbol	RCEL
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Entity Interactive Data Current	Yes
Entity Address, State or Province	CA
Entity Incorporation, State or Country Code	DE
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		21,623,287

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020
ASSETS
Cash	$ 65,753	$ 73,639
Accounts receivable, net	2,360	2,076
BARDA receivables	371	356
Prepaids and other current assets	1,054	990
Restricted cash	201	201
Inventory	1,657	1,125
Total current assets	71,396	78,387
Plant and equipment, net	1,349	1,363
Operating lease right-of-use assets	2,216	2,347
Intangible assets	403	364
Other long term assets	55	1
Total assets	75,419	82,462
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable and accrued liabilities	3,570	4,333
Accrued wages and fringe benefits	3,589	2,816
Other current liabilities	561	560
Total current liabilities	7,720	7,709
Contract liabilities	435	435
Operating lease liabilities, long term	1,776	1,917
Total liabilities	9,931	10,061
Contingencies (Note 10)
Shareholders' Equity:
Common stock, $0.0001 par value per share, 200,000,000 shares authorized, 21,623,287 and 21,467,912 shares issued and outstanding at September 30, 2020 and June 30, 2020, respectively	3	3
Preferred stock, $0.0001 par value per share, 10,000,000 shares authorized, no shares issued or outstanding at September 30, 2020 and June 30, 2020
Additional paid-in capital	262,431	259,165
Accumulated other comprehensive income	8,194	8,146
Accumulated deficit	(205,140)	(194,913)
Total shareholders' equity	65,488	72,401
Total liabilities and shareholders' equity	$ 75,419	$ 82,462

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2020	Jun. 30, 2020
Statement of Financial Position [Abstract]
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	21,623,287	21,467,912
Common stock shares outstanding	21,623,287	21,467,912
Preferred stock par value	$ 0.0001	$ 0.0001
Preferred stock shares authorized	10,000,000	10,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenues	$ 5,060	$ 3,250
Cost of sales	929	619
Gross profit	4,131	2,631
BARDA income	596	2,051
Operating expenses:
Sales and marketing expenses	2,935	2,962
General and administrative expenses	5,536	3,071
Research and development expenses	3,204	1,635
Share-based compensation	3,266	672
Total operating expenses	14,941	8,340
Operating loss	(10,214)	(3,658)
Interest expense	7	11
Other income	4	103
Loss before income taxes	(10,217)	(3,566)
Income tax benefit (expense)	10	0
Net loss	$ (10,227)	$ (3,566)
Net loss per common share:
Basic	$ 0.48	$ 0.19
Diluted	$ 0.48	$ 0.19
Weighted-average common shares:
Basic	21,503,643	18,719,857
Diluted	21,503,643	18,719,857

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net loss	$ (10,227)	$ (3,566)
Other comprehensive income gain/(loss):
Foreign currency translation gain/(loss)	48	(34)
Comprehensive loss	$ (10,179)	$ (3,600)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit
Beginning Balance at Jun. 30, 2019	$ 20,832	$ 3	$ 165,473	$ 8,184	$ (152,828)
Beginning balance, shares at Jun. 30, 2019		18,712,996
Net loss	(3,566)				(3,566)
Share-based compensation	672		672
Issuance of common stock to director in lieu of directors fees	107		107
Issuance of common stock to director in lieu of directors fees, shares		15,853
Beginning balance adjustment related ot the adoption of ASC 842	(55)				(55)
Translation gain (loss)	(34)			(34)
Ending Balance at Sep. 30, 2019	17,956	$ 3	166,252	8,150	(156,449)
Ending Balance, shares at Sep. 30, 2019		18,728,849
Beginning Balance at Jun. 30, 2020	72,401	$ 3	259,165	8,146	(194,913)
Beginning balance, shares at Jun. 30, 2020		21,467,912
Net loss	(10,227)				(10,227)
Share-based compensation	3,266		3,266
Exercise of stock options
Exercise of stock options, shares	3,538	3,538
Vesting of restricted stock units
Vesting of restricted stock units, shares		151,837
Translation gain (loss)	48			48
Ending Balance at Sep. 30, 2020	$ 65,488	$ 3	$ 262,431	$ 8,194	$ (205,140)
Ending Balance, shares at Sep. 30, 2020		21,623,287

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Cash flow from operating activities:
Net loss	$ (10,227)	$ (3,566)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	211	66
Non-cash lease expense	131	122
Loss (gain) on foreign currency transactions	80	(5)
Provision for write-down of inventories	(77)	8
Share based compensation	3,266	672
Issuance of common stock to directors in lieu of directors fees		107
Changes in operating assets and liabilities:
Trade and other receivables	(283)	(1,915)
BARDA receivables	(15)	309
Prepaids and other current assets	(65)	268
Inventory	(453)	(135)
Operating lease liability	(127)	(132)
Other long term assets	(54)	3
Accounts payable and accrued expenses	(860)	(810)
Accrued wages and fringe benefits	765	286
Other current liabilities	(5)	(155)
Other long term liabilities		(4)
Net cash used in operations	(7,713)	(4,881)
Cash flows from investing activities:
Cash paid for property and equipment	(209)	(86)
Cash paid for patent filing fees	(87)	(66)
Net cash used in investing activities	(296)	(152)
Cash flow from financing activities:
Principal repayment of finance lease	(4)	(17)
Net cash used in financing activities	(4)	(17)
Effect of foreign exchange rate on cash and restricted cash	127	(22)
Net decrease in cash and restricted cash	(7,886)	(5,072)
Cash and restricted cash at beginning of the period	73,840	20,374
Cash and restricted cash end of the period	65,954	15,302
Supplemental Disclosure of Cash Flow Information
Cash paid for income taxes	42
Cash paid for Interest	1	5
Fixed assets in accounts payable	$ 50

The Company

The Company	3 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company	1. The Company Nature of the Business The AVITA group of companies (comprising AVITA Therapeutics, Inc. (“ AVITA Therapeutics Company AVITA Medical AVITA Group we us our ® Spray-On ™ FDA PMA IDEs In March 2020, the World Health Organization declared the outbreak of a novel strain of the coronavirus (“ COVID-19 COVID-19 COVID-19, COVID-19 COVID-19 COVID-19. Redomiciliation On June 29, 2020, the Company, a newly formed Delaware corporation, acquired all of the issued share capital of AVITA Medical , a then public company incorporated under the laws of the Commonwealth of Australia and former parent company of the AVITA Group. The acquisition was completed pursuant to a scheme of arrangement under Australian law, and was approved by the Federal Court of Australia on June 22, 2020, and by shareholders of AVITA Medical on June 15, 2020 (the “ Redomiciliation ADSs CDIs ADSs NASDAQ As part of the exchange of shares under the Redomiciliation, a reverse split was also simultaneously implemented such that the number of shares of common stock on issue in AVITA Therapeutics (as set out in the condensed consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. The Redomiciliation resulted in the domicile of the AVITA Group moving from Australia to the United States of America, with AVITA Therapeutics becoming the ultimate parent company of the AVITA Group. In addition, the existing listing of AVITA Medical ordinary shares on the Australian Securities Exchange (“ ASX As a result of the Redomiciliation, the reporting currency of the AVITA Group has changed from the Australian dollar to the U.S. dollar. In accordance with SEC regulation, S-X

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP 10-Q S-X SEC 10-Q 10-K Annual Report There have been no changes to the Company’s significant accounting policies as described in the annual report on Form 10-K Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. As a result of the Redomiciliation, the parent company of the AVITA Group changed from AVITA Medical to AVITA Therapeutics. All intercompany transactions and balances have been eliminated on consolidation. Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, inventory, accounting for income taxes and share-based compensation and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts. Foreign Currency Translation The financial position and results of operations of the Company’s non-U.S. Revenue Recognition Revenues are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. Effective July 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers For the Company’s contracts that have an original duration of one year or less, the Company used the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of September 30, 2020, and June 30, 2020, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of September 30, 2020 and June 30, 2020, no single customer accounted for more than 10% of net accounts receivable. For the three months ended September 30, 2020, no single customer accounted for more than 10% of total revenues. For the three months ended September 30, 2019, one customer accounted for 13% of total revenues. BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee fixed-fee The Company has concluded that grants under the BARDA relationship is not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Accounting for Government Grants and Disclosure of Government Assistance,

Accounting Standards Update

Accounting Standards Update	3 Months Ended
	Sep. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Accounting Standards Update	3. Accounting Standards Update Recently Adopted Accounting Pronouncements In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use 350-40): set-up, internal-use Recent Accounting Pronouncements Not Yet Adopted In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes 2019-12, Income Taxes 2019-12

Leases

Leases	3 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Leases	4. Leases On July 1, 2019, the Company adopted Accounting Standards Codification No. 842, Leases right-of-use At contract inception, the Company determines whether the contract is a lease or contains a lease. A contract contains a lease if the Company is both able to identify an asset and can conclude it has the right to control the identified asset for a period of time. Leases with an initial term of twelve months or less are not recorded on the condensed consolidated balance sheet. The Company has operating leases for corporate office space, manufacturing and warehouse facility. The Company has finance leases for equipment and furniture. The Company’s leases have remaining lease terms of less than one year to five years, some of which include options to renew the lease. Approximately $7,000 and $11,000 in finance leases was included in Other current liabilities as of September 30, 2020 and June 30, 2020, respectively. ROU assets represent the Company’s right to control an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company used its incremental borrowing rate (“ IBR The Company’s lease terms are only for periods in which it has enforceable rights. A lease is no longer enforceable when both the lessee and the lessor each have the right to terminate the lease without permission from the other party with no more than an insignificant penalty. The Company has options to renew some of these leases for three years after their expiration. The Company considers these options, which may be elected at the Company’s sole discretion, in determining the lease term on a lease-by-lease Some leases require variable payments for common area maintenance, property taxes, parking, insurance, and other variable costs. The variable portion of lease payments is not included in operating lease ROU assets or operating lease liabilities. Variable lease costs are expensed when incurred. The following table sets forth the Company’s operating lease expense which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Operating lease cost $ 175 $ 175 Variable lease cost 12 12 Total lease cost $ 187 $ 187 Supplemental cash flow information related to operating leases for the three months ended September 30, 2020 and 2019 was as follows (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 171 $ 166 Supplemental balance sheet information, as of September 30, 2020 and June 30, 2020 related to operating leases was as follows (in thousands): As of September 30, As of June 30, Reported as: Operating lease right-of-use $ 2,216 $ 2,347 Total right-of-use $ 2,216 $ 2,347 Other current liabilities: Operating lease liabilities, short-term $ 548 $ 533 Operating lease liabiltiies, long term 1,776 1,917 Total operating lease liabilities $ 2,324 $ 2,450 Operating lease weighted average remaining lease term (years) 3.66 3.91 Operating lease weighted average discount rate 7.50 % 7.50 % As of September 30, 2020, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases Remaining 2021 $ 524 2022 717 2023 740 2024 588 2025 and thereafter 87 Total lease payments $ 2,656 Less imputed interest (332 ) Total operating lease liabilities $ 2,324 As of September 30, 2020, there were no leases entered into that had not yet commenced.

Inventory

Inventory	3 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Inventory	The composition of inventories is as follows (in thousands): September 30, June 30, Raw materials $ 1,035 $ 947 Work in process inventory 271 — Finished goods 351 $ 178 Total inventory $ 1,657 $ 1,125

Intangible Assets

Intangible Assets	3 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets The composition of intangible assets is as follows (in thousands): As of September 30, 2020 As of June 30, 2020 Weighted Average Life Gross Amount Accumulated Amortization Net Carry Amount Gross Amount Accumulated Amortization Net Carry Amount Patent 1 3 $ 237 $ (121 ) $ 116 $ 235 $ (101 ) $ 134 Patent 2 14 105 (9 ) 96 74 (9 ) 65 Patent 3 15 127 (11 ) 116 125 (9 ) 116 Patent 5 20 46 (1 ) 45 26 — 26 Trademarks Indefinite 30 — 30 23 — 23 Total intangible assets $ 545 $ (142 ) $ 403 $ 483 $ (119 ) $ 364 During the three months ended September 30, 2020 and 2019, the Company did not identify any events or changes in circumstances that indicated the carrying value of its intangibles may not be recoverable. As such, there was no impairment of intangibles assets recognized for the three months ended September 30, 2020 and 2019. Amortization expense of intangibles included in the condensed consolidated statements of operations was $23,000 and $0 for the three months ended September 30, 2020 and 2019, respectively. The Company expects the future amortization of amortizable intangible assets held at September 30, 2020 to be (in thousands): Estimated Amortization Expense Remainder of 2021 $ 70 2022 67 2023 21 2024 21 2025 21 2026 and thereafter 173 Total $ 373

Property, Plant and Equipment

Property, Plant and Equipment	3 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	7. Property, Plant and Equipment The composition of property, plant and equipment, net is as follows (in thousands): Useful Lives As of September 30, 2020 As of June 30, Computer equipment 3 years $ 825 $ 802 Computer software 3 years 496 369 Construction in progress 91 138 Furniture and fixtures 7 years 427 425 Laboratory equipment 5 years 233 194 Leasehold improvements Lesser of life or 216 216 RECELL Moulds 5 years 130 100 Less: accumulated amortization and depreciation (1,069 ) (881 ) Total property, plant and equipment, net $ 1,349 $ 1,363 Depreciation expense related to plant and equipment was $188,000 and $66,000 for the three months ended September 30, 2020 and 2019, respectively.

Prepaids and Other Current Asse

Prepaids and Other Current Assets	3 Months Ended
	Sep. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaids and Other Current Assets	8. Prepaids and Other Current Assets Prepaids and other current assets consisted of the following (in thousands): As of September 30, 2020 As of June 30, Prepaid expenses $ 850 $ 792 Lease deposits 98 123 Other receivables 106 75 Total prepaids and other current assets $ 1,054 $ 990 Prepaid expenses primarily consist of prepaid benefits and insurance.

Reporting Segment and Geographi

Reporting Segment and Geographic Information	3 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Reporting Segment and Geographic Information	9. Reporting Segment and Geographic Information The Company views its operations and manages its business in one reporting segment. Long-lived assets were primarily located in the United States as of September 30, 2020 and June 30, 2020 with an insignificant amount located in Australia and the United Kingdom. Revenue by region for the three months ended September 30, 2020 and 2019 were as follows (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Revenue: United States $ 4,970 $ 3,130 Foreign: Australia 80 46 United Kingdom 10 74 Total $ 5,060 $ 3,250

Contingencies

Contingencies	3 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Contingencies	10. Contingencies The Company is subject to certain contingencies arising in the ordinary course of business. The Company records accruals for these contingencies to the extent that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, that amount is accrued. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, the lowest amount in the range is accrued. The Company expenses legal costs associated with loss contingencies as incurred. As of September 30, 2020 and June 30, 2020, the Company did not have any outstanding or threatened litigation that would have a material impact to the financial statements.

Common and Preferred Stock

Common and Preferred Stock	3 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Common and Preferred Stock	11. Common and Preferred Stock On June 29, 2020, a statutory scheme of arrangement under Australian law to effect a redomiciliation of the AVITA Group from Australia to the United States of America was implemented (the “ Scheme Pursuant to the Scheme, all ordinary shares in AVITA Medical, the former parent company of the AVITA Group, were exchanged for shares of common stock in AVITA Therapeutics. As a result, AVITA Therapeutics became the sole shareholder of AVITA Medical and the new parent company of the AVITA Group. In conjunction with the Scheme, an implicit reverse split on a 1 for 100 basis was implemented whereby shareholders of AVITA Medical received one share of common stock in AVITA Therapeutics for every 100 ordinary shares held in AVITA Medical. Under the Scheme, eligible shareholders in AVITA Medical received consideration in the form of: • five CDIs in AVITA Therapeutics for every 100 ordinary shares in AVITA Medical that were held by them; or • one share of common stock in AVITA Therapeutics for every 5 ADS s The Company’s CDIs are quoted on the ASX under AVITA Medical’s existing ASX ticker code, “AVH”. The Company’s shares of common stock are quoted on NASDAQ under AVITA Medical’s existing NASDAQ ticker code, “RCEL”. One share of common stock on NASDAQ is equivalent to five CDIs on the ASX. As a result of the ‘implicit consolidation’ that occurred under the Scheme, the number of shares of common stock on issue in the Company (as set out in the condensed consolidated financial statements) is less than the number of ordinary shares in AVITA Medical that was previously set out in the consolidated financial statements of AVITA Medical. All common share amounts included in the condensed consolidated financial statements have been retroactively reduced by a factor of one hundred and all per share amounts have been increased by a factor or one hundred, with the exception of the Company’s common stock par value. The Company is authorized to issue 200,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred stock, par value $0.0001 per share, issuable in one or more series as designated by the Company’s board of directors. No other class of capital stock is authorized. As of September 30, 2020, and June 30, 2020, 21,623,287 and 21,467,912 shares of common stock, respectively, were issued and outstanding and no shares of preferred stock were outstanding.

Revenues

Revenues	3 Months Ended
	Sep. 30, 2020
Revenue, Performance Obligation [Abstract]
Revenues	12. Revenues Revenues The Company’s revenue consists of sale of the RECELL System to hospitals or other treatment centers (“customers”), predominately in the United States. Contract Assets and Contract Liabilities The Company receives payments from customers based on contractual terms. Trade receivables are recorded when the right to consideration becomes unconditional. The Company satisfies its performance obligation on product sales when the products are shipped or delivered, depending on the terms of the sale. Payment terms on invoiced amounts are typically 30-90 Contract assets include amounts related to the Company’s contractual right to consideration for both completed and partially completed performance for which the Company does not have the right to payment. As of September 30, 2020, and June 30, 2020, the Company did not have any contract assets. Contract liabilities are recorded when the Company receives payment prior to satisfying its obligation to transfer goods to a customer. The Company had $435,000 and $435,000 of contract liabilities as of September 30, 2020 and June 30, 2020, respectively. For the three months ended September 30, 2020 and 2019, revenue recognized from amounts included in the beginning balance of contract liabilities was not significant. Remaining Performance Obligations Revenues from remaining performance obligations are calculated as the dollar value of the remaining performance obligations on executed contracts. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) pursuant to the Company’s existing customer agreements is $9.6 million as of September 30, 2020. The majority of which relates to our July 13, 2020 contract with BARDA for the purchase, delivery and storage of RECELL Systems under the Strategic National Stockpile (“SNS”) for a period of three years for use in a mass casualty or other emergency situation.

Share-Based Payment Plans

Share-Based Payment Plans	3 Months Ended
	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Share-Based Payment Plans	13. Share-Based Payment Plans Overview of Employee Share-Based Compensation Plans In November 2014, our former parent company, AVITA Medical, adopted the Employee Share Plan and the Incentive Option Plan (collectively, the “2016 Plans”). The 2016 Plans previously authorized the issuance of stock options or other share-based instruments representing up to 7.5% of outstanding capital of AVITA Medical. Any increase in the maximum number of shares issuable under the 2016 Plans was subject to shareholder approval or to an increase in the total number of ordinary shares outstanding. Upon Redomiciliation, the 2016 Plans were terminated with respect to future grants and accordingly, there are no more shares available to be issued under the 2016 Plans. In addition, upon Redomiciliation, the Company had an implicit 100-1 Share-Based Payment Expenses Share-based payment transactions are recognized as compensation cost based on the fair value of the instrument on the date of grant. The Company uses the binomial option valuation model to estimate the grant date fair value of employee stock options. During the three months ended September 30, 2020 and 2019, the Company recorded stock-based compensation expense of $3.2 million and $672,000, respectively. No income tax benefit was recognized in the condensed consolidated statement of comprehensive loss for share-based payment arrangements for the three months ended September 30, 2020 and 2019. A summary of stock option activity under the employees share option plan Service Only Stock Options Performance Based Stock Options Total Stock Options Outstanding at June 30, 2020 904,353 356,171 1,260,524 Exercised (3,538 ) — (3,538 ) Expired (1,636 ) (2 ) (1,638 ) Forfeited (21,778 ) — (21,778 ) Outstanding at September 30, 2020 877,401 356,169 1,233,570 Exercisable at September 30, 2020 296,803 298,897 595,700 Restricted Stock Units Restricted stock units (“ RSUs A summary of the status of the Company’s unvested shares as of September 30, 2020, and changes during the three months ended September 30, 2020, is presented below: Service Condition Performance Condition RSUs Total RSU Unvested RSUs outstanding at June 30, 2020 95,013 244,346 339,359 Vested — (151,837 ) (151,837 ) Forfeited — (2 ) (2 ) Unvested RSUs outstanding at September 30, 2020 95,013 92,507 187,520

Income Taxes

Income Taxes	3 Months Ended
	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	14. Income Taxes At June 30, 2020, the Company and its subsidiaries had net operating loss carryforwards for U.S. federal, state, United Kingdom, and Australian income tax purposes of $88.5 million, $57.5 million, $29.8 million, and $34.1 million, respectively. The net operating loss carryforwards may be subject to limitation regarding their utilization against taxable income in future periods due to “change of ownership” provisions of the Internal Revenue Code and similar state and foreign provisions. Of these carryforwards, $21.7 million will expire, if not utilized, in various years through 2038. The remaining loss carryforwards have no expiration. In assessing the recoverability of its deferred tax assets, the Company considers whether it is more likely than not that its deferred assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income in those periods in which temporary differences become deductible and/or net operating losses can be utilized. The Company considers all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income. Based upon the weight of available evidence including the uncertainty regarding the Company’s ability to utilize certain net operating losses and tax credits in the future, the Company has established a full valuation allowance against all its net deferred tax assets. The deferred tax assets are primarily net operating loss carryforwards for which management has determined it is more likely than not that the deferred tax assets will not be realized. The Company recognizes the tax benefit from an uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the condensed consolidated financial statements related to a particular tax position are measured based on the largest benefit that has a greater than a 50% likelihood of being realized upon settlement. The amount of unrecognized tax benefits is adjusted as appropriate for changes in facts and circumstances, such as significant amendments to existing tax law, new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, or resolution of an examination. The Company has not identified any uncertain tax positions as of September 30, 2020 or June 30, 2020. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“ CARES Ac

Net Loss per Share

Net Loss per Share	3 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Net Loss per Share	15. Net Loss per Share The following is a reconciliation of the basic and diluted loss per share computations: Three Months Ended September 30, 2020 2019 (in thousands, expect per share data) Net Loss $ 10,227 $ 3,56 6 Weighted-average common shares - outstanding, basic 21,504 18,720 Weighted-average common shares - outstanding, diluted 21,504 18,720 Net loss per common share, basic $ 0.48 $ 0.19 Net loss per common share, diluted $ 0.48 $ 0.19 The Company’s basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the relevant period. For the purposes of the calculation of diluted net loss per share options to purchase common stock, restricted stock units and unvested shares of common stock issued upon the early exercise of stock options have been excluded from the calculation of diluted net loss per share as their effect is anti-dilutive. Because the Company has reported a net loss for the three months ended September 30, 2020 and 2019, diluted net loss per common share is the same as the basic net loss per share for those periods. The loss per share incorporates the impact of the reverse stock split that was effectuated in conjunction with the Redomicilation. In accordance with ASC 260, the impact of the reverse stock split was retrospectively applied for all periods presented.

Retirement Plans

Retirement Plans	3 Months Ended
	Sep. 30, 2020
Retirement Benefits [Abstract]
Retirement Plans	16. Retirement Plans The Company offers a 401(k)-retirement savings plan (the “401(k) Plan”) for its employees, including its executive officers, who satisfy certain eligibility requirements. The Internal Revenue Code of 1986, as amended, allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax

Subsequent Events

Subsequent Events	3 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	17. Subsequent Events The Company has considered all events occurring subsequent to September 30, 2020 and has concluded that all significant events have been disclosed in the condensed consolidated financial statements and accompanying notes.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“ GAAP 10-Q S-X SEC 10-Q 10-K Annual Report There have been no changes to the Company’s significant accounting policies as described in the annual report on Form 10-K
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. As a result of the Redomiciliation, the parent company of the AVITA Group changed from AVITA Medical to AVITA Therapeutics. All intercompany transactions and balances have been eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of the accompanying condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts including doubtful accounts, carrying value of long-lived asset, the useful lives of long-lived assets, inventory, accounting for income taxes and share-based compensation and related disclosures. Estimates have been prepared on the basis of the current and available information. However, actual results could differ from estimated amounts.
Foreign Currency Translation	Foreign Currency Translation The financial position and results of operations of the Company’s non-U.S.
Revenue Recognition	Revenue Recognition Revenues are recognized as control of the product is transferred to customers, at an amount that reflects the consideration expected to be received in exchange for the product. Revenues are recognized net of volume discounts. As such, revenue is recognized only to the extent a significant reversal of revenues is not expected to occur in subsequent periods. Effective July 1, 2018, the Company adopted ASC 606, Revenue from Contracts with Customers For the Company’s contracts that have an original duration of one year or less, the Company used the practical expedient applicable to such contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of each reporting period or when the Company expects to recognize this revenue. The Company has further applied the practical expedient to exclude sales tax in the transaction price and expense contract fulfilment costs such as commissions and shipping and handling expenses as incurred.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, and trade and other receivables. As of September 30, 2020, and June 30, 2020, substantially all of the Company’s cash was deposited in accounts at financial institutions, and amounts exceed federally insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which its cash is held. As of September 30, 2020 and June 30, 2020, no single customer accounted for more than 10% of net accounts receivable. For the three months ended September 30, 2020, no single customer accounted for more than 10% of total revenues. For the three months ended September 30, 2019, one customer accounted for 13% of total revenues.
BARDA Income and Receivables	BARDA Income and Receivables The AVITA Group was awarded a Biomedical Advance Research and Development Authority (“ BARDA Consideration received under the BARDA arrangement is earned and recognized under a cost-plus-fixed-fee fixed-fee The Company has concluded that grants under the BARDA relationship is not within the scope of ASC 606, as it does not meet the definition of a contract with a “customer.” The Company has further concluded that Subtopic 958-605, Not-for-Profit-Entities-Revenue Accounting for Government Grants and Disclosure of Government Assistance,

Leases (Tables)

Leases (Tables)	3 Months Ended
	Sep. 30, 2020
Leases [Abstract]
Summary Of Lease Cost	The following table sets forth the Company’s operating lease expense which are included in general and administrative expenses in the consolidated statements of operations (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Operating lease cost $ 175 $ 175 Variable lease cost 12 12 Total lease cost $ 187 $ 187
Summary Of Supplemental Cash Flow Information Related To Operating Leases	Supplemental cash flow information related to operating leases for the three months ended September 30, 2020 and 2019 was as follows (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash outflows from operating leases $ 171 $ 166
Summary Of Supplemental Balance Sheet Information Related To Operating Leases	Supplemental balance sheet information, as of September 30, 2020 and June 30, 2020 related to operating leases was as follows (in thousands): As of September 30, As of June 30, Reported as: Operating lease right-of-use $ 2,216 $ 2,347 Total right-of-use $ 2,216 $ 2,347 Other current liabilities: Operating lease liabilities, short-term $ 548 $ 533 Operating lease liabiltiies, long term 1,776 1,917 Total operating lease liabilities $ 2,324 $ 2,450 Operating lease weighted average remaining lease term (years) 3.66 3.91 Operating lease weighted average discount rate 7.50 % 7.50 %
Summary Of Maturities Of The Company's Operating Lease Liabilities	As of September 30, 2020, maturities of the Company’s operating lease liabilities are as follows (in thousands): Operating Leases Remaining 2021 $ 524 2022 717 2023 740 2024 588 2025 and thereafter 87 Total lease payments $ 2,656 Less imputed interest (332 ) Total operating lease liabilities $ 2,324

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Sep. 30, 2020
Inventory Disclosure [Abstract]
Summary Of Composition Of Inventories	The composition of inventories is as follows (in thousands): September 30, 2020 June 30, 2020 Raw materials $ 1,035 $ 947 Work in process inventory 271 — Finished goods 351 $ 178 Total inventory $ 1,657 $ 1,125

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Summary Of Composition Of Intangible Assets	The composition of intangible assets is as follows (in thousands) As of September 30, 2020 As of June 30, 2020 Weighted Average Life Gross Amount Accumulated Amortization Net Carry Amount Gross Amount Accumulated Amortization Net Carry Amount Patent 1 3 $ 237 $ (121 ) $ 116 $ 235 $ (101 ) $ 134 Patent 2 14 105 (9 ) 96 74 (9 ) 65 Patent 3 15 127 (11 ) 116 125 (9 ) 116 Patent 5 20 46 (1 ) 45 26 — 26 Trademarks Indefinite 30 — 30 23 — 23 Total intangible assets $ 545 $ (142 ) $ 403 $ 483 $ (119 ) $ 364
Summary Of Future Amortization Of Amortizable Intangible Assets Held	The Company expects the future amortization of amortizable intangible assets held at September 30, 2020 to be (in thousands): Estimated Amortization Expense Remainder of 2021 $ 70 2022 67 2023 21 2024 21 2025 21 2026 and thereafter 173 Total $ 373

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	3 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Summary Of Composition Of Property, Plant And Equipment	The composition of property, plant and equipment, net is as follows (in thousands): Useful Lives As of September 30, 2020 As of June 30, Computer equipment 3 years $ 825 $ 802 Computer software 3 years 496 369 Construction in progress 91 138 Furniture and fixtures 7 years 427 425 Laboratory equipment 5 years 233 194 Leasehold improvements Lesser of life or 216 216 RECELL Moulds 5 years 130 100 Less: accumulated amortization and depreciation (1,069 ) (881 ) Total property, plant and equipment, net $ 1,349 $ 1,363

Prepaids and Other Current As_2

Prepaids and Other Current Assets (Tables)	3 Months Ended
	Sep. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Schedule Of Prepaids And Other Current Assets	Prepaids and other current assets consisted of the following (in thousands): As of September 30, 2020 As of June 30, Prepaid expenses $ 850 $ 792 Lease deposits 98 123 Other receivables 106 75 Total prepaids and other current assets $ 1,054 $ 990

Reporting Segment and Geograp_2

Reporting Segment and Geographic Information (Tables)	3 Months Ended
	Sep. 30, 2020
Segment Reporting [Abstract]
Schedule Of Revenue By Region	Revenue by region for the three months ended September 30, 2020 and 2019 were as follows (in thousands): Three Months ended September 30, 2020 Three Months ended September 30, 2019 Revenue: United States $ 4,970 $ 3,130 Foreign: Australia 80 46 United Kingdom 10 74 Total $ 5,060 $ 3,250

Share-Based Payment Plans (Tabl

Share-Based Payment Plans (Tables)	3 Months Ended
	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Stock Option Activity	A summary of stock option activity under the employees share option plan Service Only Stock Options Performance Based Stock Options Total Stock Options Outstanding at June 30, 2020 904,353 356,171 1,260,524 Exercised (3,538 ) — (3,538 ) Expired (1,636 ) (2 ) (1,638 ) Forfeited (21,778 ) — (21,778 ) Outstanding at September 30, 2020 877,401 356,169 1,233,570 Exercisable at September 30, 2020 296,803 298,897 595,700
Non Option Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Stock Option Activity	A summary of the status of the Company’s unvested shares as of September 30, 2020, and changes during the three months ended September 30, 2020, is presented below: Service Condition Performance Condition RSUs Total RSU Unvested RSUs outstanding at June 30, 2020 95,013 244,346 339,359 Vested — (151,837 ) (151,837 ) Forfeited — (2 ) (2 ) Unvested RSUs outstanding at September 30, 2020 95,013 92,507 187,520

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Sep. 30, 2020
Earnings Per Share [Abstract]
Summary Of Reconciliation Of The Basic And Diluted Loss Per Share	The following is a reconciliation of the basic and diluted loss per share computations: Three Months Ended September 30, 2020 2019 (in thousands, expect per share data) Net Loss $ 10,227 $ 3,56 6 Weighted-average common shares - outstanding, basic 21,504 18,720 Weighted-average common shares - outstanding, diluted 21,504 18,720 Net loss per common share, basic $ 0.48 $ 0.19 Net loss per common share, diluted $ 0.48 $ 0.19

The Company - Additional Inform

The Company - Additional Information (Detail)	3 Months Ended
	Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of stock exchange ratio	This exchange was conducted on the basis of one share of common stock of AVITA Therapeutics for every 100 ordinary shares of AVITA Medical, effecting an ‘implicit consolidation’ or ‘reverse split’. The holders of ordinary shares of AVITA Medical received one CDI for every 20 ordinary shares held in AVITA Medical, and the holders of AVITA Medical ADSs (each of which previously represented 20 ordinary shares in AVITA Medical) received one share of common stock in AVITA Therapeutics for every five ADSs held.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2020
Concentration risk, customer	0	0	0
Revenue Benchmark
Concentration risk, percentage	10.00%	10.00%	10.00%
Revenue Benchmark | Customer One [Member]
Concentration risk, percentage		13.00%

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)	Sep. 30, 2020	Jun. 30, 2020	Jul. 01, 2019
Leases [Line Items]
Finance lease liability	$ 7,000	$ 11,000
Minimum
Leases [Line Items]
Remaining lease terms			1 year
Maximum
Leases [Line Items]
Remaining lease terms			5 years

Leases - Summary Of Lease Cost

Leases - Summary Of Lease Cost (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Lease Cost [Line Items]
Operating lease cost	$ 175	$ 175
Variable lease cost	12	12
Total lease cost	$ 187	$ 187

Leases - Summary Of Supplementa

Leases - Summary Of Supplemental Cash Flow Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Disclosure Of Supplemental cash flow information related to operating leases [Line Items]
Operating cash outflows due to operating leases	$ 171	$ 166

Leases - Summary Of Supplemen_2

Leases - Summary Of Supplemental Balance Sheet Information Related To Operating Leases (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020
Disclosure Of Supplemental Balance Sheet Information Related To Operating Leases [Line Items]
Operating lease right-of-use assets	$ 2,216	$ 2,347
Total right-of-use assets	2,216	2,347
Operating lease liabilities, short-term	548	533
Operating lease liabiltiies, long term	1,776	1,917
Total operating lease liabilities	$ 2,324	$ 2,450
Operating lease weighted average remaining lease term (years)	3 years 7 months 27 days	3 years 10 months 27 days
Operating lease weighted average discount rate	7.50%	7.50%

Leases - Summary Of Maturities

Leases - Summary Of Maturities Of The Company's Operating Lease Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020
Lessee Operating Lease Liability Maturity [Line Items]
Remaining 2021	$ 524
2022	717
2023	740
2024	588
2025 and thereafter	87
Total lease payments	2,656
Less imputed interest	(332)
Total operating lease liabilities	$ 2,324	$ 2,450

Inventory - Summary Of Composit

Inventory - Summary Of Composition Of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020
Inventory [Line Items]
Raw materials	$ 1,035	$ 947
Work in process inventory	271
Finished goods	351	178
Total inventory	$ 1,657	$ 1,125

Inventory - Additional Informat

Inventory - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventory impairments	$ 43,000	$ 53,000

Intangible Assets - Summary Of

Intangible Assets - Summary Of Composition Of Intangible Assets (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 30	$ 23
Intangible Assets, Gross (Excluding Goodwill)	545	483
Finite Lived Intangible Assets, Accumulated Amortization	(142)	(119)
Finite Lived Intangible Assets, Net Carrying Amount	373
Intangible Assets, Net (Excluding Goodwill)	403	364
Trademarks
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 30	23
Patent 1
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years
Finite Lived Intangible Assets, Gross Amount	$ 237	235
Finite Lived Intangible Assets, Accumulated Amortization	(121)	(101)
Finite Lived Intangible Assets, Net Carrying Amount	$ 116	134
Patent 2
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	14 years
Finite Lived Intangible Assets, Gross Amount	$ 105	74
Finite Lived Intangible Assets, Accumulated Amortization	(9)	(9)
Finite Lived Intangible Assets, Net Carrying Amount	$ 96	65
Patent 3
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	15 years
Finite Lived Intangible Assets, Gross Amount	$ 127	125
Finite Lived Intangible Assets, Accumulated Amortization	(11)	(9)
Finite Lived Intangible Assets, Net Carrying Amount	$ 116	116
Patent 5
Schedule Of Intangible Assets Excluding Goodwill [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Finite Lived Intangible Assets, Gross Amount	$ 46	26
Finite Lived Intangible Assets, Accumulated Amortization	(1)
Finite Lived Intangible Assets, Net Carrying Amount	$ 45	$ 26

Intangible Assets - Additional

Intangible Assets - Additional Information (Details) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Impairment of intangible assets	$ 0	$ 0
Amortization of intangible assets	$ 23,000	$ 0

Intangible Assets - Summary o_2

Intangible Assets - Summary of Future Amortization of Amortizable Intangible assets held (Detail) $ in Thousands	Sep. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2021	$ 70
2022	67
2023	21
2024	21
2025	21
2026 and thereafter	173
Total	$ 373

Property, Plant and Equipment -

Property, Plant and Equipment - Summary Of Composition Of Property, Plant And Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Jun. 30, 2020
Property, Plant and Equipment [Line Items]
Less: accumulated amortization and depreciation	$ (1,069)	$ (881)
Total property, plant and equipment, net	$ 1,349	1,363
Computer Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 825	802
Computer Software
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property, Plant and Equipment, Gross	$ 496	369
Construction In Progress
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 91	138
Furniture And Fixtures
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Property, Plant and Equipment, Gross	$ 427	425
Laboratory Equipment
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 233	194
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	0 months
Property, Plant and Equipment, Gross	$ 216	216
RECELL Moulds
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Property, Plant and Equipment, Gross	$ 130	$ 100

Property, Plant and Equipment_2

Property, Plant and Equipment - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Property, Plant and Equipment [Abstract]
Depreciation	$ 188,000	$ 66,000

Prepaids and Other Current As_3

Prepaids and Other Current Assets - Schedule Of Prepaids And Other Current Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2020	Jun. 30, 2020
Prepaid expenses	$ 850	$ 792
Lease deposits	98	123
Other receivables	106	75
Total prepaids and other current assets	$ 1,054	$ 990

Reporting Segment and Geograp_3

Reporting Segment and Geographic Information - Schedule Of Revenue By Region (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Revenue :
Revenues	$ 5,060	$ 3,250
United States
Revenue :
Revenues	4,970	3,130
Foreign | Australia
Revenue :
Revenues	80	46
Foreign | United Kingdom
Revenue :
Revenues	$ 10	$ 74

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Threatened Litigation
Litigation liability	$ 0	$ 0

Common and Preferred Stock - Ad

Common and Preferred Stock - Additional Information (Detail)	Jun. 29, 2020	Sep. 30, 2020$ / sharesshares	Jun. 30, 2020$ / sharesshares
Class of Stock [Line Items]
Common stock shares authorized		200,000,000	200,000,000
Common stock par value | $ / shares		$ 0.0001	$ 0.0001
Common stock shares issued		21,623,287	21,467,912
Common stock shares outstanding		21,623,287	21,467,912
Preferred stock shares authorized		10,000,000	10,000,000
Preferred stock par value | $ / shares		$ 0.0001	$ 0.0001
Preferred stock shares outstanding		0	0
Shareholders Of Avita Medical
Class of Stock [Line Items]
Reverse stock split ratio	0.01
CDI | Shareholders Of Avita Medical
Class of Stock [Line Items]
Reverse stock split ratio	0.05
Common Stock | Shareholders Of Avita Medical | ADRS
Class of Stock [Line Items]
Reverse stock split ratio	0.05

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - USD ($)	Sep. 30, 2020	Jun. 30, 2020
Revenue, Performance Obligation [Abstract]
Contract with customer assets	$ 0	$ 0
Contract with customers non current liability	435,000	$ 435,000
Performance obligation estimated revenue expected to be recognised	$ 9,600,000

Share-Based Payment Plans - Add

Share-Based Payment Plans - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation expense	$ 3,266,000	$ 672,000
Income tax benefit (expense)	$ (10,000)	$ 0
Employee Share Plan And Incentive Option Plan Two Thousand And Sixteen
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstading share capital authorised for issuance share based plan			7.50%
Share based compensation by share based payment arrangement weighted average grant date of fair value of options granted		$ 0
Share based compensation by share based payment arrangement intrinsic value of options exercised		$ 0
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation by share based payment arrangement other than options total fair value of shares vested		$ 0
Share based compensation by share based payment arrangement other than option weighted average grant date fair value		$ 0

Share-Based Payment Plans - Sum

Share-Based Payment Plans - Summary Of Stock Option Activity (Detail)	3 Months Ended
	Sep. 30, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	1,260,524
Exercised	(3,538)
Expired	(1,638)
Forfeited	(21,778)
Ending balance	1,233,570
Exercisable	595,700
Service Only Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	904,353
Exercised	(3,538)
Expired	(1,636)
Forfeited	(21,778)
Ending balance	877,401
Exercisable	296,803
Performance Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	356,171
Expired	(2)
Ending balance	356,169
Exercisable	298,897

Share-Based Payment Plans - S_2

Share-Based Payment Plans - Summary Of Company Unvested Shares (Detail)	3 Months Ended
	Sep. 30, 2020shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	339,359
Unvested shares vested	(151,837)
Unvested shares forfeited	(2)
Unvested shares ending balance	187,520
Non Options Service Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	95,013
Unvested shares vested	0
Unvested shares forfeited	0
Unvested shares ending balance	95,013
Non Option Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested shares beginning balance	244,346
Unvested shares vested	(151,837)
Unvested shares forfeited	(2)
Unvested shares ending balance	92,507

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2018
Income Tax Disclosure [Line Items]
Unrecognised income tax benenfits	$ 0	$ 0
Tax Cut And Jobs Act
Income Tax Disclosure [Line Items]
Percentage of tax amount likely to be realised	50.00%	50.00%	50.00%	50.00%
Tax Year 2038
Income Tax Disclosure [Line Items]
Net operating loss carryforwards		$ 21,700,000
Internal Revenue Service (IRS)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards		88,500,000
State and Local Jurisdiction
Income Tax Disclosure [Line Items]
Net operating loss carryforwards		57,500,000
Her Majesty's Revenue and Customs (HMRC)
Income Tax Disclosure [Line Items]
Net operating loss carryforwards		29,800,000
Australian Taxation Office
Income Tax Disclosure [Line Items]
Net operating loss carryforwards		$ 34,100,000

Net Loss per Share - Summary of

Net Loss per Share - Summary of Reconciliation of The Basic And Diluted Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Loss	$ 10,227	$ 3,566
Weighted-average common shares - outstanding, basic	21,503,643	18,719,857
Weighted-average common shares - outstanding, diluted	21,503,643	18,719,857
Net loss per common share, basic	$ (0.48)	$ (0.19)
Net loss per common share, diluted	$ (0.48)	$ (0.19)

Retirement Plans - Additional I

Retirement Plans - Additional Information (Detail) - USD ($)	3 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Retirement Benefits [Abstract]
Defined contribution plan employers matching contribution percentage of employees pay	6.00%
Employers contribution to retirement plan	$ 165,000	$ 154,000